A phase I study of the heparanase inhibitor: PI-88 and weekly docetaxel in patients (PTS) with advanced solid malignancies.

被引：0
|
作者：
Raj, SKS
Basche, M
Gore, L
Grolnic, S
Hunt, J
O'Bryant, CL
Morrow, M
Creese, B
Kangas, M
Sawlwin, D
Eckhardt, SG
Holden, SN
Holden, SN
机构：
[1] Univ Colorado, Ctr Canc, Aurora, CO USA
[2] Progen Ind Ltd, Darra, Australia
[3] Omnicare Clin Res, Sydney, NSW, Australia
来源：
CLINICAL CANCER RESEARCH | 2003年 / 9卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：6152S / 6152S
页数：1
相关论文
共 50 条
  • [21] Phase I study of weekly docetaxel and liposomal doxorubicin in patients with advanced solid tumors
    Kouroussis, C
    Androulakis, N
    Vamvakas, L
    Kalykaki, A
    Spiridonakou, S
    Kentepozidis, N
    Saridaki, Z
    Xiropoulou, E
    Georgoulias, V
    ONCOLOGY, 2005, 69 (03) : 202 - 207
  • [22] A phase I study of lenalidomide and weekly docetaxel in patients with advanced solid tumors.
    Papadopoulos, K
    Mendelson, D
    Preston, GG
    Lopez, AM
    Ricart, AD
    Schwartz, G
    Needle, MN
    Gordon, MS
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9116S - 9116S
  • [23] A phase I study of the selective apoptotic antineoplastic drug (SAAND) OSI-461 in patients (pts) with advanced solid malignancies.
    O'Bryant, CL
    Holden, SN
    Basche, M
    Raj, SS
    Witta, S
    Gore, L
    Grolnic, S
    Brillhart, B
    Hunt, J
    Schultz, MK
    Morrow, M
    Gibbs, A
    Barrett, E
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6163S - 6163S
  • [24] First-in-human, phase I, dose-escalation study of selective PI3Kα isoform inhibitor MLN1117 in patients (pts) with advanced solid malignancies.
    Juric, Dejan
    De Bono, Johann Sebastian
    LoRusso, Patricia
    Nemunaitis, John J.
    Heath, Elisabeth I.
    Kwak, Eunice Lee
    Macarulla, Teresa
    Geuna, Elena
    Luken, Maria Jose de Miguel
    Patel, Chirag
    Kuida, Keisuke
    Sankoh, Serap
    Zohren, Fabian
    Shou, Yaping
    Tabernero, Josep
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [25] A phase I study to evaluate safety, tolerability, pharmacokinetics and activity of oraxol in patients (pts) with advanced malignancies.
    Ma, Wen Wee
    Azad, Nilofer Saba
    Lam, Elaine Tat
    Diamond, Jennifer Robinson
    Dy, Grace K.
    Opyrchal, Mateusz
    Gallagher, Denise
    Brennen, Caden
    Cutler, David
    Kramer, Douglas
    Chan, Wing Kai
    Kwan, Rudolf
    Fetterly, Gerald J.
    Adjei, Alex A.
    Jimeno, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [26] Phase I study of aflibercept in combination with docetaxel in Japanese patients with advanced solid malignancies
    Sunakawa, Yu
    Takahashi, Keishiro
    Kawaguchi, Osamu
    Yamamoto, Nobuyuki
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (05) : 1032 - 1041
  • [27] Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies
    Mita, Monica
    Mita, Alain
    Sarantopoulos, John
    Takimoto, Chris H.
    Rowinsky, Eric K.
    Romero, Ofelia
    Angiuli, Patrizia
    Allievi, Cecilia
    Eisenfeld, Amy
    Verschraegen, Claire F.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (02) : 287 - 295
  • [28] A phase I study of HYB2055 in patients (pts) with advanced solid malignancies
    Hwang, JJ
    Park, S
    Amin, A
    Martin, RR
    Sullivan, T
    Burns, T
    Agrawal, S
    Waxdal, MJ
    Malik, S
    Marshall, JL
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 222S - 222S
  • [29] Phase I study of aflibercept in combination with docetaxel in Japanese patients with advanced solid malignancies
    Yu Sunakawa
    Keishiro Takahashi
    Osamu Kawaguchi
    Nobuyuki Yamamoto
    Investigational New Drugs, 2022, 40 : 1032 - 1041
  • [30] A phase I study of docetaxel and 5-fluorouracil in patients with advanced solid malignancies
    Petit, T
    Aylesworth, C
    Burris, H
    Ravdin, P
    Rodriguez, G
    Smith, L
    Peacock, N
    Smetzer, L
    Bellet, R
    Von Hoff, DD
    Rowinsky, EK
    ANNALS OF ONCOLOGY, 1999, 10 (02) : 223 - 229
12345